Background. Better understanding of complications and outcomes of adults hospitalized with respiratory syncytial virus (RSV) infection is necessary.
burden of RSV can approach that of influenza [3, [5] [6] [7] [8] . However, except, perhaps, in the profoundly immunosuppressed, little is known about the clinical manifestations, complications, and outcomes of severe RSV infections in adults. Factors associated with severe and fatal infections are largely unknown. Data from Asian countries are particularly scarce [9] [10] [11] [12] .
This study examined a large cohort of adults hospitalized with laboratory-confirmed RSV infections in Hong Kong, China. Clinical, laboratory, and radiological findings were reported and analyzed to identify factors associated with pneumonia development, respiratory failure, and death. Their severity of illness and outcomes were compared with patients admitted for seasonal influenza during the same period. Such information, when available, not only improves our understanding on severe RSV disease in adults and its impact on the healthcare system, but also provides valuable data to support future planning of clinical trials on RSV therapeutics and prevention.
METHODS

Study Population and Case Finding Procedures
A retrospective cohort study on hospitalized adults with RSV infections was conducted. All patients aged ≥18 years admitted to 1 of the 3 participating medical units between 1 January 2009 and 31 December 2011 (ie, 36 months) with laboratoryconfirmed RSV infections were studied (N = 607). In Hong Kong, peak RSV activities occur in spring or summer, or both, with yearly variations [12, 13] . No case was excluded from the analysis. All 3 participating hospitals (A, B, and C) are acute care, general public hospitals operating under the Hospital Authority of Hong Kong. The 3 hospitals serve an urban population of >1.5 million accounting for >20% of the population in Hong Kong [14, 15] . The Hospital Authority is the main provider of acute medical care in Hong Kong. Ethical approval for the study was obtained from the institutional review boards of the Hospital Authority of Hong Kong and the Chinese University of Hong Kong.
During the study period, respiratory viral infections including RSV and influenza in the hospitalized adults were prospectively diagnosed according to a standard protocol as part of patients' routine care, as previously described [14] [15] [16] . In brief, patients presenting with symptoms of acute respiratory infections were admitted if they developed potentially serious medical conditions and/or if their exacerbation of chronic illnesses or their severe symptoms were considered to be impossible to be managed at home [14, 16] . Nasopharyngeal aspirates (NPAs) were collected at presentation from all such patients, regardless of perceived etiology and disease severity, to test for RSV and influenza antigens using an immunofluorescence assay (see next section) [4, 12, [14] [15] [16] . In a minority of cases where NPA cannot be performed, nasopharyngeal flocked swabs were collected for testing. Test results were generally made available to physicians within a few hours to assist patient management and infection control precautions. In addition, chest radiography was performed at admission for all patients, and sputum samples were routinely collected for bacterial culture. Blood cultures were also performed when there were signs of sepsis [14] [15] [16] .
Data Collection and Definitions of Variables
All patients with laboratory-confirmed RSV infections admitted during the study period were identified from a computerized laboratory record system. Patients' electronic (hospital Clinical Management System [CMS]) and written records were reviewed, and the clinical and laboratory information was systematically recorded using a standardized research tool [14] [15] [16] . Clinical data collected included demographics, comorbidities, illness onset time, presenting symptoms, cardiorespiratory complications, requirement for supplemental oxygen therapy and/or ventilatory support, antibiotic use, use of systemic corticosteroids (eg, intravenous hydrocortisone, oral prednisolone), hospitalization duration, and all-cause death. Laboratory data included routine blood test results and bacterial pathogens cultured from respiratory and/or blood samples at presentation and during hospitalization [14] . Pneumonia was defined as physician-diagnosed pneumonia based on symptoms and signs of acute lower respiratory tract infection together with new pulmonary infiltrates on a patient's chest radiographs [5, [14] [15] [16] [17] . Acute respiratory failure requiring ventilatory support was defined as persistent respiratory failure despite supplemental oxygen therapy (eg, SaO 2 <92%) which necessitated the use of noninvasive positive pressure ventilation (NIPPV) or invasive mechanical ventilation for support [14, 15] . The main outcome measure in this analysis was all-cause death; the secondary outcome measures were (1) development of acute respiratory failure requiring ventilatory support and (2) total duration of hospitalization among survivors [14, 15] . In addition, we compared the RSV patients with a cohort of patients admitted to these hospitals for seasonal influenza in 2009-2011 [14, 15] . The same research tools and definitions were used for both study cohorts. Patients hospitalized with pandemic 2009 H1N1 infections were not included for comparison as they were significantly younger and shown to have a different clinical course compared to seasonal influenza, as described elsewhere [15] .
Virological Investigations
All NPAs collected were subjected to viral antigen detection for a panel of respiratory viruses including RSV, influenza A and B, and parainfluenza 1, 2, and 3 viruses using an immunofluorescence assay (IFA) as previously described [14] [15] [16] . NPA contained more abundant epithelial cells for immunofluorescence staining; false-positive results are rare (see Discussion) [3, 4, 12, [18] [19] [20] .
In brief, NPA samples were washed with phosphate-buffered saline. The cells were fixed on the wells of a glass slide with acetone and stained with respiratory virus-specific antibodies (LIGHT DIAGNOSTICS Respiratory Syncytial Virus FITC Reagent, Chemicon/Millipore). Specific fluorescent signals were cross-checked by 2 experienced technicians and reviewed by clinical virologists. A repeat sample would be requested if necessary. Virus isolation was performed for all influenza cases using methods previously described (but not routinely for RSV because of its low sensitivity and logistic demands) [4, 16, 12] .
Radiographic Assessment
To further characterize RSV-related lower respiratory tract complications and their impacts in adults, additional, detailed radiographic review was performed for all RSV cases admitted to the largest study site (hospital A, n = 286; 47% of the entire cohort). The chest radiographs at admission were reviewed by 2 independent, experienced radiologists using dedicated Picture Archiving and Communication System workstations in retrospect; images were interpreted in consensus for the few discrepant cases [21] [22] [23] . The reviewers were blinded to all clinical information of patients and their outcomes. Previous chest radiographs were used for comparison whenever available (86%). The chest radiographs were assessed for the presence of any active lung parenchymal changes (including consolidation, ground glass opacity, and reticulonodular shadows) that were compatible with the diagnosis of pneumonia, and their patterns and extent [22, 23] . Radiologists' reviews were considered final.
Statistical Analysis
The Student t, Mann-Whitney U, and χ 2 tests with continuity correction were used for univariate comparisons whenever appropriate. Variables with P values < .1 in the univariate analyses were entered into multivariate Cox proportional hazards models (backward, stepwise regression) to determine independent factors associated with death that occurred within 30 days and 60 days from time of hospitalization [6, 8, 14, 15] . Variables including demographics, comorbidities, cardiorespiratory complications, ventilation requirement, bacterial superinfection, and corticosteroid use were examined. Adjusted hazard ratios (AHRs) and 95% confidence intervals (CIs) were calculated for each explanatory variable. An AHR >1 indicated a higher chance of death. A Kaplan-Meier curve was constructed to show survival of patients with or without pneumonia development, and compared using the log-rank test. Cox regression models were also used to determine independent factors associated with time to hospital discharge. Multivariate logistic regression was used to analyze factors associated with pneumonia and acute respiratory failure requiring ventilatory support; adjusted odds ratios (AORs) and 95% CIs were reported for explanatory variables [14] [15] [16] . Analyses of clinical outcomes were performed for the whole cohort, and repeated in the subgroup with additional radiographic reviews performed. We also compared the manifestations and outcomes of RSV patients to a concurrent seasonal influenza cohort using similar analytic methods [14, 15] . All probabilities were 2-tailed, and a P value of <.05 was considered to indicate statistical significance. We also calculated a conservative, Bonferroni-adjusted P value threshold (P < .002) for the multiple comparisons in Table 1 for reference. Statistical analysis was performed using PASW Statistics software, version 18.0.
RESULTS
Patient Descriptions and Clinical Manifestations
During the 3-year study period, a total of 607 RSV cases were diagnosed among the hospitalized adults: 2009, n = 123; 2010, n = 237; 2011, n = 247. The median RSV-positive rate among submitted respiratory samples during the seasonal peaks of the years was: 5.8% (interquartile range [IQR], 4.8%-6.5%), 6.6% (IQR, 5.8%-9.8%), and 9.1% (IQR, 5.7%-13.7%), respectively ( Figure 1 ). Patients' baseline characteristics and clinical manifestations are described in Table 1 . The mean and median ages were 75 (SD, 16) years and 80 (IQR, 68-86) years, respectively; 87.3% had 1 or more coexisting medical conditions (eg, chronic lung diseases, 35.6%, major systemic comorbidities, 74.0%; immunocompromised, 13.7%; see Table 1 ). The mean and median time of admission from symptom onset was 2.6 (SD, 2.2) days and 2 (IQR, 1-3) days, respectively. Fever (75.0%), cough (87.5%), sputum production (81.2%), and wheezy breathing and dyspnea (68.9%) were the commonest presenting symptoms. One or more complications were documented in 80.4%. Lower respiratory tract complications were diagnosed in 71.9%, including pneumonia (42.3%), acute bronchitis (21.9%), and exacerbation of chronic obstructive pulmonary disease (COPD)/asthma (with or without pneumonia, 27.3%). Bacterial superinfection was evidenced in 12.5% at presentation; Streptococcus pneumoniae, Haemophilus influenzae, and Pseudomonas aeruginosa were the commonest isolates (Table 1) . Cardiovascular complications (eg, exacerbation of heart failure, acute coronary events) were diagnosed in 14.3% of patients. Among the subset of patients with additional radiographic review performed, 141 of 286 (49.3%) had shown active pneumonic changes; consolidations (23.8%) and ground-glass opacities (19.9%) were the commonest findings. Most (81.8%) changes were unilateral. Examples of patients' chest radiographs at presentation are shown in Figure 2 . Symptoms associated with radiographic pneumonia included fever (82.0% pneumonia vs 72.5% without pneumonia, P = .058) and wheezy breathing and dyspnea (79.9% vs 66.2%, P = .010). Runny nose (23.7% vs 35.2%, P = .035) and sore throat (9.4% vs 16.2%, P = .086) were less common. Multivariate analysis showed that presence of Outcomes of Hospitalized Adults With RSV • CID 2013:57 (15 October) • 1071 major systemic comorbidities (AOR, 1.85; 95% CI, 1.05-3.26) and elevated white blood cell counts (AOR, 1.07; 95% CI, 1.01-1.13, per unit increase) were independently associated with radiographic pneumonia, adjusted for demographic and bacteriological variables (Supplementary Data 1).
Patient Management and Outcomes
Systemic corticosteroids were given to 38.9% of patients to treat acute airway diseases (eg, COPD/asthma exacerbations), and antibiotics were used in 94.7% of cases. Two-thirds (67.9%) of patients were given supplemental oxygen therapy; 11.1% developed persistent respiratory failure and required ventilatory support (NIPPV, 9.1%, invasive ventilation, 2.0%). Underlying chronic lung diseases, pneumonia ( particularly the presence of ground-glass opacities), and elevated serum urea and alanine aminotransferase levels were shown to be independent factors associated with requirement of ventilatory support ( Table 2) . The crude all-cause mortality within 30 days and 60 days of this RSV cohort was 9.1% (n = 55) and 11.9% (n = 72), respectively. The median time to death was 13 (IQR, 7-29) days after admission (90th percentile, 45 days). The reported direct causes of death were pneumonia (n = 48), COPD exacerbation (n = 5), acute cardiovascular events (n = 12), and underlying medical conditions complicated by pneumonia/sepsis (n = 7) (Table 3) . For the survivors, the median and mean durations of hospitalization were 7 (IQR, 5-14) days and 12 (SD, 13) days, respectively.
Development of pneumonia in adult RSV patients was associated with lower survival; mortality within 30 days and 60 days for pneumonia cases was 15.6% (vs 4.3%) and 20.3% (vs 5.7%), respectively ( Figure 3 ). Cox regression analyses showed that advanced age >75 years, pneumonia, requirement for ventilatory support, bacterial superinfection, and elevated serum urea level and white blood cell count were independent factors associated with lower survival, adjusted for potential confounders (Table 4 ; Supplementary Data 2). Use of systemic corticosteroids was not shown to be associated with survival. However, advanced age, presence of comorbidities, requirement for ventilatory support, and use of systemic corticosteroids were shown to be independently associated with longer hospitalization durations (Table 5 ; Supplementary Data 2). Rates of cultureproven, hospital-acquired bacterial infection were higher in patients who received corticosteroids than in those who did not (4.3% vs 1.1%, P = .012).
Comparisons With Seasonal Influenza
When patients with RSV were compared with hospitalized patients with seasonal influenza (n = 547), we found that patients with RSV infections were similar in age but more frequently had underlying chronic lung diseases and major systemic comorbidities; time to presentation was longer; wheezy breathing and dyspnea was more frequent; and high fever was less common (Table 1) . Substantial proportions of patients in both cohorts had cardiorespiratory complications. Rates of use of supplemental oxygen and assisted ventilation tended to be higher among RSV patients, but there was no significant difference in 6 .6% (IQR, 5.8%-9.8%), and 9.1% (IQR, 5.7%-13.7%), respectively [12, 13] . Abbreviation: RSV, respiratory syncytial virus. 
DISCUSSION
Our data show that RSV can cause severe lower respiratory complications in older adults, resulting in respiratory failure, prolonged hospitalization, and high mortality similar to influenza. Corticosteroids did not seem to improve clinical outcomes. The unmet need for effective antiviral therapy and vaccination against RSV in adults should be promptly addressed.
To our knowledge, this study describes the largest adult cohort of hospitalized RSV patients reported to date, and represents one of the few studies performed in Asia [9] [10] [11] . Consistent with data from Western countries, such patients were mostly of advanced age and had underlying chronic lung diseases or other major medical comorbidities [3] [4] [5] 17] ; notably, >70% suffered from severe lower respiratory complications, including pneumonia, acute bronchitis, and exacerbations of COPD/asthma, and 14% developed cardiovascular complications [7, 17] . Although fulminant RSV pneumonia is typically described in patients who are profoundly immunosuppressed (eg, recipients of hematopoietic stem cell transplant) [2, 3, 24] , we found clinicoradiological evidence of pneumonia (unilateral, patchy, ground glass opacity or consolidation) in >40% of these hospitalized adults, which was associated with high fever, dyspnea, and respiratory failure (more than two-thirds of cases required supplemental oxygen) [2] [3] [4] [5] 17] . Upper respiratory symptoms of runny nose and sore throat could be absent [2-4, 6, 17, 21] . Importantly, we documented the poor outcomes of adults hospitalized for RSV infection: >10% of cases necessitated ventilatory support and the overall death rate exceeded 10% [2, 4, 5] . Pneumonic cases were shown to have the worst prognosis, with a ventilation rate of about 15% and mortality as high as 15%-20%. For the survivors, prolonged hospitalization was often required for the management of cardiorespiratory complications (eg, COPD exacerbation, congestive heart failure) [5] . Late deaths occurred because of secondary infections, cardiovascular events, or decompensation of comorbid conditions (Table 3 ) [6, 8] .
Furthermore, we were able to show that among hospitalized adults, clinical manifestations, complications, and outcomes of RSV infection are comparable to those of seasonal influenza (majority being A/H3N2 in this series) [3, 5, 6] . Although in RSV patients, wheezy breathing and dyspnea might be more common, and the magnitude of fever sometimes lower, such symptoms Covariates in the model (subgroup) included age, sex, major systemic comorbidity, culture-confirmed bacterial superinfection, and serum urea concentration at presentation.
Abbreviation: RSV, respiratory syncytial virus. a Additional radiographic review performed by independent radiologists.
b Presence vs absence of ground-glass opacities on chest radiographs, as confirmed by radiologists. Altogether, 72 patients died within 60 days postadmission; 52 (72.2%) had pneumonia diagnosed at presentation. The 50th, 75th, and 90th percentiles of time to death were 13, 29, and 45 days postadmission, respectively.
Abbreviations: CAPD, continuous ambulatory peritoneal dialysis; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal.
could not reliably differentiate it from influenza [3, 4, 17] . High rates of respiratory (56%-72%) and cardiovascular (13%-14%) complications occurred in both infections, with substantial proportions of patients requiring supplemental oxygen therapy (59%-68%) and ventilatory support (6%-11%) [5, 6] . Respiratory failure appeared to be more common among RSV patients, but there was a higher prevalence of chronic lung diseases among them. The overall outcomes of survival and hospitalization duration were not shown to be significantly different between RSV and influenza patients after adjustment for confounders [4] [5] [6] [7] [8] [9] . Unlike influenza, antiviral treatment or vaccine is currently not available for RSV. Ribavirin and immunoglobulins have been used to treat (or prevent) severe RSV pneumonia in immunocompromised patients; however, controlled data are lacking, and whether these can be applied to the older adults are uncertain [3, 4, [24] [25] [26] . Our findings thus highlight the need for therapeutic and preventive interventions against RSV in adults. Recent progress on their development and the obstacles encountered has been reviewed elsewhere [3, 4, 24] . In addition, we examined the roles of bacterial infections and systemic corticosteroids in adult RSV infections. We found evidence of bacterial superinfection in about 15% of patients during their course of illness, which was a significant contributory factor to mortality (similar in influenza diseases) [4, 5, 9, 15, 17] .
As such, any bacterial infection should be promptly detected and treated according to local resistance profiles. Besides S. pneumoniae and H. influenzae, P. aeruginosa and other gram-negative bacilli may need to be considered in patients with underlying chronic lung diseases [4, 9, 15] . Corticosteroids Patients who developed pneumonia were shown to have lower survival. Among RSV patients who had pneumonia, the crude 30-day and 60-day mortality was 15.6% and 20.3%, respectively (4.3% and 5.7%, respectively, in those without pneumonia). Subgroup analysis on cases with additional radiograph reviews showed similar results (data not shown).
are commonly used to treat wheezy attacks and exacerbations of COPD/asthma in adults, including those triggered by viral infections [16, 27] . In this large RSV cohort, we did not observe any benefit on clinical outcomes with systemic corticosteroid treatment in the multivariate analyses, adjusted for disease severity. Instead, increased bacterial infections and longer hospitalization duration were found. Limiting our analysis to a patient subset presenting with wheezy breathing and dyspnea showed similar results (data not shown). We cannot eliminate indication bias, but these findings are supported by randomized controlled trials in young children, which revealed lack of clinical benefit and inconsistent control of inflammatory cytokine responses with corticosteroids [28] [29] [30] . A recent adult study reported similar findings; it also showed that humoral immunity against RSV was diminished, although virus control appeared unaffected [31] . Emerging evidence suggests worse outcomes with corticosteroid use in influenza pneumonia [16, 32] . Taken together, it is suggested that the decision to treat RSV patients with corticosteroids should be weighed against the potential risks, and be limited to a short course if used [4, 25, 31] . Further study is indicated. The strengths of our study include a large sample size, multicenter design, and virological confirmation of cases. Identical clinical settings and research methods had allowed more precise comparisons between the 2 viral infections. Chest radiographs were independently reviewed; the detailed findings will be reported separately [22] . Our study is limited by its retrospective nature; therefore, variables least prone to bias were chosen as outcome measures, and confounders adjusted carefully in multivariate analyses. The use of IFA instead of PCR for the diagnosis of RSV in our service settings could also be a limitation. IFA is highly specific (95%-99%), and moderately sensitive (80%-94%, higher with NPA) in children; the sensitivity in adults is generally lower because of lower virus shedding levels [3, 4, 12, [18] [19] [20] 33] . Although increased test sensitivity can be expected in the older, hospitalized adults with severe RSV disease because of their higher viral titers and longer virus shedding durations [34] [35] [36] , it is possible that some cases, especially the milder ones, had remained undetected. Using PCR (without or without paired serology) for diagnosis should reveal a greater disease burden [4, 34] . We have planned to perform PCR, neutralizing antibodies, and virus subtyping in our patients in the near future (evidence suggests that both serotypes A and B circulate in Asia) [10] .
In conclusion, adults hospitalized for RSV infection have high morbidity and mortality, comparable to outcomes in influenza patients. Studies on disease pathogenesis (eg, viral dynamics, immune response, viral-bacterial interactions) [3, 4, [34] [35] [36] ; strategies to improve case finding, diagnosis, and infection control in the hospital setting (eg, PCR, serology, aerosol transmission) [3, 4, 17, 34, 35, 37] ; and development of antiviral therapies and immunization of high-risk adults (eg, small interfering RNA, fusion protein inhibitor, newer generation immunoglobulins, subunit vaccines) [3, 4, 24, 38, 39] are urgently needed.
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